IL13 and nasal cavity polyp: Dupilumab is a fully human VelocImmune-derived monoclonal antibody that functions by blocking the shared receptor subunit for interleukin (IL)-4 and IL-13, thereby inhibiting the signaling of these two cytokines and reducing type 2 inflammation associated with atopic dermatitis (AD) and related atopic diseases such as asthma, allergic rhinitis, food allergy, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis (34, 35).